TY - JOUR
T1 - Phenotypic spectrum of the recurrent TRPM3 p.(Val837Met) substitution in seven individuals with global developmental delay and hypotonia
AU - TUDP Study Group
AU - Lines, Matthew A
AU - Goldenberg, Paula
AU - Wong, Ashley
AU - Srivastava, Siddharth
AU - Bayat, Allan
AU - Hove, Hanne
AU - Karstensen, Helena Gásdal
AU - Anyane-Yeboa, Kwame
AU - Liao, Jun
AU - Jiang, Nan
AU - May, Alison
AU - Guzman, Edwin
AU - Morleo, Manuela
AU - D'Arrigo, Stefano
AU - Ciaccio, Claudia
AU - Pantaleoni, Chiara
AU - Castello, Raffaele
AU - McKee, Shane
AU - Ong, Jinfon
AU - Zibdeh-Lough, Hana
AU - Tran-Mau-Them, Frederic
AU - Gerasimenko, Anna
AU - Heron, Delphine
AU - Keren, Boris
AU - Margot, Henri
AU - de Sainte Agathe, Jean-Madeleine
AU - Burglen, Lydie
AU - Voets, Thomas
AU - Vriens, Joris
AU - Innes, A Micheil
AU - Dyment, David A
N1 - © 2022 Wiley Periodicals LLC.
PY - 2022/6
Y1 - 2022/6
N2 - TRPM3 encodes a transient receptor potential cation channel of the melastatin family, expressed in the central nervous system and in peripheral sensory neurons of the dorsal root ganglia. The recurrent substitution in TRPM3: c.2509G>A, p.(Val837Met) has been associated with syndromic intellectual disability and seizures. In this report, we present the clinical and molecular features of seven previously unreported individuals, identified by exome sequencing, with the recurrent p.(Val837Met) variant and global developmental delay. Other shared clinical features included congenital hypotonia, dysmorphic facial features (broad forehead, deep-set eyes, and down turned mouth), exotropia, and musculoskeletal issues (hip dysplasia, hip dislocation, scoliosis). Seizures were observed in two of seven individuals (febrile seizure in one and generalized tonic-clonic seizures with atonic drops in another), and epileptiform activity was observed in an additional two individuals. This report extends the number of affected individuals to 16 who are heterozygous for the de novo recurrent substitution p.(Val837Met). In contrast with the initial report, epilepsy was not a mandatory feature observed in this series. TRPM3 pathogenic variation should be considered in individuals with global developmental delays, moderate-severe intellectual disability with, or without, childhood-onset epilepsy.
AB - TRPM3 encodes a transient receptor potential cation channel of the melastatin family, expressed in the central nervous system and in peripheral sensory neurons of the dorsal root ganglia. The recurrent substitution in TRPM3: c.2509G>A, p.(Val837Met) has been associated with syndromic intellectual disability and seizures. In this report, we present the clinical and molecular features of seven previously unreported individuals, identified by exome sequencing, with the recurrent p.(Val837Met) variant and global developmental delay. Other shared clinical features included congenital hypotonia, dysmorphic facial features (broad forehead, deep-set eyes, and down turned mouth), exotropia, and musculoskeletal issues (hip dysplasia, hip dislocation, scoliosis). Seizures were observed in two of seven individuals (febrile seizure in one and generalized tonic-clonic seizures with atonic drops in another), and epileptiform activity was observed in an additional two individuals. This report extends the number of affected individuals to 16 who are heterozygous for the de novo recurrent substitution p.(Val837Met). In contrast with the initial report, epilepsy was not a mandatory feature observed in this series. TRPM3 pathogenic variation should be considered in individuals with global developmental delays, moderate-severe intellectual disability with, or without, childhood-onset epilepsy.
U2 - 10.1002/ajmg.a.62673
DO - 10.1002/ajmg.a.62673
M3 - Article
C2 - 35146895
SN - 1552-4825
VL - 188
SP - 1667
EP - 1675
JO - American Journal of Medical Genetics, Part A
JF - American Journal of Medical Genetics, Part A
IS - 6
ER -